Mpox (Monkeypox): In- Depth Insight at the Current State of the Global Health Crisis - Etiology, Epidemiology, Detection, Treatment and Prevention Strategies | Chapter 4 | Disease and Health Research: New Insights Vol. 9

Mpox, formerly known as the Monkeypox Virus, is once again in the headlines announcing its comeback. While still recovering from the 2022 outbreak - the World Health Organization (WHO), for the second time in as many years has declared mpox to be a global health emergency. The same uphill battle is being faced at the outset of this recurring threat. Mpox is a known quantity to the scientific community and has been for more than 60 years. First identified in humans during the 1970s, mpox is a viral zoonotic infectious disease transmitted from animals to humans and humans to humans. It is caused by the mpox virus - an enveloped double-stranded DNA virus belonging to the orthopoxvirus family. It is largely relegated to the tropical rainforests of Central and West Africa. It has been mostly ignored in Europe and the Americas until just recently when it has generated worldwide attention. Cases of the mpox infection first appeared sporadically amongst gay and bisexual men with Europe first reporting cases in mid-2022. Shortly thereafter, occurrences were seen in the metropolitan areas of New York, Chicago, San Francisco and Los Angeles. The 2022 outbreak was a turning point with over 100 countries reporting cases which had not previously been seen before. Mpox infections are transmitted through close personal contact with infected individuals, infected animals or mpox-tainted materials. The WHO has declared mpox a “Public Health Emergency of International Concern”. There are two distinct s of the mpox virus - Clade I and Clade II. Clade I’s origins have historically been linked to the Congo Basin, while Clade II’s origins have historically been linked to Western Africa. In 2022 the global outbreak was caused by Clade IIb and most recently, by Clade Ib in 2024. Mpox is genetically similar to smallpox. Although no treatment for the mpox virus exists, supportive care, antivirals and vaccines developed for smallpox have proven effective. Individuals infected with mpox demonstrate skin rashes and mucosal lesions accompanied by fever, chills, headaches, muscle aches, back pain, low energy, sore throat, and cough. These symptoms are similar to those infected with smallpox, but much more attenuated in nature. After a 3-week incubation period, mpox goes away on its own in approximately 2-5 weeks. Diagnostic testing and disease confirmation are performed via RT-PCR testing of genetic material from the infected areas and through the presence of lymphadenopathy (i.e. enlarged lymph nodes). This distinct symptom is what differentiates those who are infected with mpox versus those who are infected with either smallpox or chickenpox.

 

Author (s) Details

 

M Waheed Roomi
Spandidos Publications, 5-6, King Street Cloisters, Clifton Walk, London W6 0GY, United Kingdom.

 

Please see the book here:- https://doi.org/10.9734/bpi/dhrni/v9/2652

Deciphering Mpox: Understanding Pathophysiology, Perception, and Strategies for the Concerned Approach | Chapter 14 | New Visions in Medicine and Medical Science Vol. 2

 Recent advancements have furthered our understanding of Mpox pathogenesis, highlighting the virus's complex interactions with the human immune system. Studies now emphasize the critical role of mRNA vaccines in providing a potent immune response, underscoring the potential for broader protective measures against the virus. While the globe struggles to contain the Coronavirus disease- 19 (COVID-19) pandemic, the upsurge of isolated cases of other viral diseases like Monkey pox (Mpox) has raised alarm. On July 23, 2022, the world health organization (WHO) director-general, Tedros Adhanom Ghebreyesus, PhD, overruled the WHO Emergency Committee (EC), which had voted 6-9 against declaring a public health emergency of international concern (PHEIC), and declared the current Mpox outbreak a PHEIC. In the lack of easily accessible prophylaxis or treatment, prompt case identification is critical for containment. The fact that some of the nine cases of mpox reported in India have no travel history, indicating that the disease may spread through droplet infection, nucleus, or aerosol transmission, is concerning the general public. The latest outbreak in Europe and North America is most likely sustained by human-to-human transmission, unlike the cases discovered in Africa, according to the letter’s authors. The virus can transfer from one person to another through direct contact with lesions, bodily fluids, respiratory droplets, or fomites. However, the infection is typically a zoonosis in the African continent. Besides, the reluctance of people to even disclose when they have symptoms owing to social stigma, adds to the challenge. To combat the common misconceptions, the researchers demanded an ‘urgent’ revision to the term ‘Mpox.’ In contrast to smallpox, Mpox disease remains endemic in some parts of the world (primarily West and Central Africa). The outlook is better for the West African clade, which has a case fatality rate (CFR) of less than 1%. Whereas, the Central Basin clade (also called the Central African clade) is more deadly, with a CFR of up to 11% in young unvaccinated individuals. New research highlights advanced understanding of Mpox pathogenesis, including detailed virus localization in tissues, especially in immunocompromised patients. Studies show severe or fatal outcomes are more common in these groups, emphasizing the need for targeted surveillance and management strategies.

Author(s) Details:

Shazia Naaz,
Department of Microbiology, Mamata Academy of Medical Sciences, Bachupally, Hyderabad, Telangana, India.

Lakshmi Jyothi,
Department of Microbiology, All India Institute of Medical Sciences, Bibinagar, Yadadri Dist, Telangana, India.

Please see the link here: https://stm.bookpi.org/NVMMS-V2/article/view/13837

Human Mpox: A Deadliest Pox Virus till Date | Chapter 10 | Research Advances in Microbiology and Biotechnology Vol. 8

 The continuous 2022 multicountry outbreak of Mpox (monkey pox) is an arising and re-emerging Zoonotic viral ailment. Mpox is a double-stranded DNA bug. It can be transmitted to persons through physical contact with dignitary who is infectious, accompanying contaminated materials, or with contaminated animals. It draws world’s consideration because of the increasing incident of human outbreaks recent years, further its traditional terrestrial location. The incubation ending of the disease maybe 5 to 21 days. The current 2022 outbreak of Mpox in newly stated countries primarily influences men (homosexual or epicene) and genital skin lesions are a dominant syndrome. Genome sequencing has revealed that the Clade IIb variant arrange the Mpox ourbreak. Healthcare professionals are at higher risk of flattering infected since they are in close trade patients directly. Children, meaningful women & people accompanying weak invulnerable system are at risk for difficulty from Mpox.The WHO declared, Mpox as a public health crisis of international concern on 25 July 2022. So, it is important to amend knowledge of this zoonotic contamination, including case judgment, contact tracing, laboratory review, clinical management, seclusion and implementation of infection stop control measures and prophylaxis to understand the more extensive implication of the current plague. WHO published a strategic readiness & response plan for Mpox.CDC admits use of stockpiled Tecovirimat to Mpox during an outbreak. VIGIV is licenced by FDA for the situation of complications on account of vaccinia vaccination. A newer cure based on modified weakened vaccinia virus (Ankara strain) was approved for the stop of Mpox.

Author(s) Details:

Meenu Meena,
Govt. Medical College, Kota, Affiliated to Rajasthan University of Health Sciences and Rajasthan University, India.

Please see the link here: https://stm.bookpi.org/RAMB-V8/article/view/12630